Viral hepatitis and pregnancy

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/108668/1/cld367.pd

Reply

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149229/1/hep30564.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149229/2/hep30564_am.pd

Personalized treatment of hepatitis B

There are seven approved drugs for treatment of hepatitis B. Professional guidelines provide a framework for managing patients but these guidelines should be interpreted in the context of the individual patient's clinical and social circumstances. Personalized management of hepatitis B can be applied based on prediction of the individual patient's risk of cirrhosis and hepatocellular carcinoma to guide the frequency and intensity of monitoring and urgency of treatment. It can also be applied to decisions regarding when to start treatment, which drug to use, and when to stop based on the individual patient's disease characteristics, preference, comorbidities and other mitigating circumstances

Optimizing medication management for patients with cirrhosis: Evidence‐based strategies and their outcomes

Cirrhosis is a morbid condition associated with frequent hospitalizations and high mortality. Management of cirrhosis requires complex medication regimens to treat underlying liver disease, complications of cirrhosis and comorbid conditions. This review examines the complexities of medication management in cirrhosis, barriers to optimal medication use, and potential interventions to streamline medication regimens and avoid medication errors. A literature review was performed by searching PUBMED through December 2017 and article reference lists to identify articles relevant to medication management, complications, adherence, and interventions to improve medication use in cirrhosis. The structural barriers in cirrhosis include sheer medication complexity related to the number of medications and potential for cognitive impairment in this population, faulty medication reconciliation and limited adherence. Tested interventions have included patient self‐education, provider driven patient education, intensive case management including medication blister packs and smartphone applications. Initiatives are needed to improve patient, caregiver and provider education on appropriate use of medications in patients with cirrhosis. A multidisciplinary team should be established to coordinate care with close monitoring, address patient and caregiver concerns, and to provide timely access to outpatient evaluation of urgent/complex issues. Future studies evaluating the clinical outcomes and cost effectiveness of interventions are needed.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146454/1/liv13892_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146454/2/liv13892.pd

Hepatitis B cure: From discovery to regulatory approval

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138245/1/hep29323.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138245/2/hep29323_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138245/3/hep29323-sup-0001-supptable1.pd

Model‐free scoring system for risk prediction with application to hepatocellular carcinoma study

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142930/1/biom12750_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142930/2/biom12750-sup-0001-SuppData-S1.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142930/3/biom12750.pd

Acceptance and use of a smartphone application in cirrhosis

Background and AimsThe development of cirrhosis‐related smartphone applications for remote monitoring is increasing. Whether patients with cirrhosis will welcome such new technology, however, is uncertain.MethodsWe prospectively enrolled patients with cirrhosis (N = 102) to determine predictors of acceptance and utilization of a smartphone application for cirrhosis management using a 12‐item Technology Acceptance Model (TAM) survey. Patients were then shown the EncephalApp© and evaluated for their willingness to download and use the application.ResultsPatients had a median age of 61.3 years and 63.7% had a history of hepatic decompensation. Intention to use the hypothetical application was associated with perceived usefulness (β: 0.4, 95% CI: 0.3‐0.5) and the presence of a caregiver (β: 1.1, 95% CI: 0.2‐2.0). Of the eligible participants, 71% agreed to download the EncephalApp© and the decision was influenced by computer anxiety, behavioural intent, caregiver presence and disease state factors. Actual usage was 32% and not associated with baseline characteristics or the technology acceptance model.ConclusionsPatient acceptance of smartphone applications for the management of cirrhosis is high and related to their attitudes towards technology and the presence of a caregiver. However, usage was low. Future research must employ behavioural interventions to optimize uptake and utilization of remote monitoring technology.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/155977/1/liv14494_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/155977/2/liv14494.pd

Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient‐Reported Outcomes in Cirrhosis

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/1/hep30336-sup-0001-Supinfo.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/2/hep30336_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148384/3/hep30336.pd

Reply

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142921/1/hep29806_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/142921/2/hep29806.pd

Occult hepatitis B virus infection: A hidden menace?

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/34784/1/510340128_ftp.pd